Ligand Pharmaceuticals Incorporated
LGND
$159.40
$0.610.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 187.58M | 181.49M | 167.13M | 152.42M | 133.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 187.58M | 181.49M | 167.13M | 152.42M | 133.48M |
| Cost of Revenue | 79.79M | 78.58M | 32.50M | 32.37M | 33.26M |
| Gross Profit | 107.79M | 102.91M | 134.63M | 120.06M | 100.22M |
| SG&A Expenses | 89.06M | 86.50M | 78.65M | 69.04M | 59.22M |
| Depreciation & Amortization | 33.03M | 33.03M | 32.96M | 33.04M | 33.02M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 201.88M | 198.11M | 144.11M | 134.45M | 125.50M |
| Operating Income | -14.30M | -16.63M | 23.02M | 17.98M | 7.98M |
| Income Before Tax | -84.50M | -161.11M | 2.52M | 58.82M | 53.01M |
| Income Tax Expenses | -8.63M | -28.49M | 6.55M | 13.57M | 10.87M |
| Earnings from Continuing Operations | -75.86 | -132.62 | -4.03 | 45.24 | 42.14 |
| Earnings from Discontinued Operations | -- | -- | -- | 0.00 | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.86M | -132.62M | -4.03M | 45.24M | 42.14M |
| EBIT | -14.30M | -16.63M | 23.02M | 17.98M | 7.98M |
| EBITDA | 19.73M | 18.16M | 58.26M | 53.50M | 43.94M |
| EPS Basic | -3.99 | -7.12 | -0.05 | 2.63 | 2.43 |
| Normalized Basic EPS | -0.72 | -0.81 | 0.52 | 0.11 | 0.37 |
| EPS Diluted | -4.00 | -7.12 | -0.16 | 2.51 | 2.31 |
| Normalized Diluted EPS | -0.73 | -0.81 | 0.52 | 0.11 | 0.36 |
| Average Basic Shares Outstanding | 75.91M | 74.61M | 73.15M | 71.65M | 70.61M |
| Average Diluted Shares Outstanding | 76.51M | 74.61M | 73.54M | 72.25M | 71.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |